EDESA BIOTECH, INC.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $780.0K | $0 | $328.8K | $0 | $228.3K | $1.3M | $758.7K | $372.1K |
| Cost of Revenue | — | $0 | $17.6K | $0 | $250.0K | $818.6K | $580.8K | $469.1K |
| Gross Profit | — | $0 | $311.2K | $0 | $-21.8K | $453.1K | $177.9K | $-97.0K |
| Gross Margin | — | — | 94.6% | — | -9.5% | 35.6% | 23.4% | -26.1% |
| Operating Expenses | ||||||||
| Research & Development | $13.3M | $17.9M | $3.3M | $1.1M | $2.0M | $1.7M | $1.0M | $2.5M |
| SG&A Expense | $5.0M | $5.7M | $3.4M | $543.2K | $2.9M | $3.3M | $3.2M | $2.9M |
| Operating Income | $-18.4M | $-23.7M | $-6.4M | $-1.6M | $-5.2M | $-4.9M | $-4.3M | $-5.7M |
| Operating Margin | -2,355.2% | — | -1,946.7% | — | -2,288.6% | -386.0% | -571.9% | -1,536.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-17.5M | $-13.3M | — | $-5.0M | $-5.0M | $-5.0M | $-2.8M | $-8.4M |
| Income Tax Expense | $800 | $800 | $800 | $0 | $800 | $7.2K | $36.8K | $27.2K |
| Net Income | $-17.5M | $-13.3M | $-6.4M | $-1.5M | $-5.0M | $-5.0M | $-2.8M | $-8.4M |
| Net Margin | -2,249.9% | — | -1,935.3% | — | -2,203.7% | -395.2% | -374.7% | -2,267.9% |
| EPS (Basic) | — | $-1.10 | $-0.74 | $-0.47 | $-3.44 | $-0.57 | $-0.36 | $-1.11 |
| EPS (Diluted) | — | $-1.10 | $-0.74 | $-0.47 | $-3.44 | $-0.57 | $-0.36 | $-1.11 |
| Shares Outstanding (Basic) | 19.4M | 13.5M | 10.5M | 3.2M | 10.5M | 8.8M | 8.0M | 7.6M |
| Shares Outstanding (Diluted) | 19.4M | 13.5M | 10.5M | 3.2M | 10.5M | 8.8M | 8.0M | 7.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |